Inflammation-based Prognostic Score As a Prognostic Biomarker in Patients With Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy

Overview

Journal In Vivo

Specialty Oncology

Date 2022 Mar 4

PMID 35241549

Authors

Mioko Matsuo

Ryuji Yasumatsu

Muneyuki Masuda

Satoshi Toh

Takahiro Wakasaki

Kazuki Hashimoto

Rina Jiromaru

Tomomi Manako

Takashi Nakagawa

Affiliations

Soon will be listed here.

Abstract

Background/aim: The inflammation-based prognostic score (IBPS) has attracted attention recently as a prognostic biomarker for head and neck cancer patients. However, as the IBPS often changes after anticancer drug therapy, its independent prognostic value remains controversial. We aimed to investigate the relationship between the IBPS and prognosis in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with nivolumab, and investigate changes in the IBPS before and after nivolumab treatment.

Patients And Methods: Total of 164 patients with RMHNSCC received nivolumab therapy were retrospectively analyzed.

Results: Univariate analysis among the 164 patients revealed that the performance status (PS), immune-related adverse event (irAE) status, pre- and post-therapy Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and post-eosinophil count, were all significant predictors of overall survival (OS) (p<0.05). A multivariate analysis revealed that PS, irAEs, post-GPS, post-NLR, post-CAR, and post-eosinophil count were independent prognostic factors for overall survival.

Conclusion: Post-treatment factors were identified as independent prognostic factors for RMHNSCC and can more accurately predict prognosis compared to nivolumab-treated RMHNSCC pre-treatment factors.

Citing Articles

Baseline (modified) Glasgow prognostic score as a predictor of therapeutic response to immune checkpoint inhibitors in solid tumors: A systematic review and meta‑analysis.

Ye H, Li M Oncol Lett. 2025; 29(4):184.

PMID: 40007624 PMC: 11851447. DOI: 10.3892/ol.2025.14931.

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.

Zhang X, Zhang B, Li D, Yang Y, Lin S, Zhao R Front Immunol. 2025; 16:1528084.

PMID: 39949762 PMC: 11821924. DOI: 10.3389/fimmu.2025.1528084.

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.

Su J, Li Y, Tan S, Cheng T, Luo Y, Zhang L Sci Rep. 2025; 15(1):446.

PMID: 39747391 PMC: 11695637. DOI: 10.1038/s41598-024-84890-3.

Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer.

Ueda N, Kuroki M, Shibata H, Matsubara M, Akita S, Yamada T Cancers (Basel). 2024; 16(23).

PMID: 39682242 PMC: 11640115. DOI: 10.3390/cancers16234056.

Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab.

Kasahara Y, Saijo K, Ueta R, Numakura R, Sasaki K, Yoshida Y Sci Rep. 2024; 14(1):28255.

PMID: 39548176 PMC: 11568322. DOI: 10.1038/s41598-024-79130-7.

References

Mohammed F, Poon I, Zhang L, Elliott L, Hodson I, Sagar S . Acute-phase response reactants as objective biomarkers of radiation-induced mucositis in head and neck cancer. Head Neck. 2011; 34(7):985-93. DOI: 10.1002/hed.21848. View

Kim J, Jung E, Kim J, Lee H, Kwag S, Park J . Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer. 2020; 20(1):1206. PMC: 7720486. DOI: 10.1186/s12885-020-07700-9. View

Wu Y, Li C, Zhao J, Yang L, Liu F, Zheng H . Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis. World J Surg Oncol. 2016; 14(1):289. PMC: 5112720. DOI: 10.1186/s12957-016-1044-9. View

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

Crumley A, Stuart R, McKernan M, McDonald A, McMillan D . Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2007; 23(8 Pt 2):e325-9. DOI: 10.1111/j.1440-1746.2007.05105.x. View

Rassouli A, Saliba J, Castano R, Hier M, Zeitouni A . Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck. 2013; 37(1):103-10. DOI: 10.1002/hed.23567. View

Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Kadowaki S . Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Sci. 2020; 112(1):339-346. PMC: 7780035. DOI: 10.1111/cas.14706. View

Sato H, Tsubosa Y, Kawano T . Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg. 2012; 36(3):617-22. DOI: 10.1007/s00268-011-1411-1. View

Ikeguchi M . Glasgow prognostic score and neutrophil-lymphocyte ratio are good prognostic indicators after radical neck dissection for advanced squamous cell carcinoma in the hypopharynx. Langenbecks Arch Surg. 2016; 401(6):861-6. DOI: 10.1007/s00423-016-1453-9. View

10.

Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I . Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers (Basel). 2019; 11(9). PMC: 6770631. DOI: 10.3390/cancers11091317. View

11.

McCourt M, Wang J, Sookhai S, Redmond H . Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol. 2001; 27(4):396-403. DOI: 10.1053/ejso.2001.1133. View

12.

Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K . Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 2016; 7(47):77404-77415. PMC: 5363594. DOI: 10.18632/oncotarget.12677. View

13.

Dolan R, Laird B, Horgan P, McMillan D . The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review. Crit Rev Oncol Hematol. 2018; 132:130-137. DOI: 10.1016/j.critrevonc.2018.09.016. View

14.

Sun P, Chen C, Xia Y, Bi X, Liu P, Zhang F . The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma. Dis Markers. 2017; 2017:6570808. PMC: 5476879. DOI: 10.1155/2017/6570808. View

15.

Takenaka Y, Oya R, Kitamiura T, Ashida N, Shimizu K, Takemura K . Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta-analysis. Head Neck. 2018; 40(12):2714-2723. DOI: 10.1002/hed.25366. View

16.

Turri-Zanoni M, Salzano G, Lambertoni A, Giovannardi M, Karligkiotis A, Battaglia P . Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. Head Neck. 2016; 39(4):730-736. DOI: 10.1002/hed.24681. View

17.

Mikoshiba T, Ozawa H, Saito S, Ikari Y, Nakahara N, Ito F . Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients. Anticancer Res. 2019; 39(6):3059-3065. DOI: 10.21873/anticanres.13440. View

18.

Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K . Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol. 2019; 101:104525. DOI: 10.1016/j.oraloncology.2019.104525. View

19.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

20.

Shibutani M, Maeda K, Nagahara H, Iseki Y, Hirakawa K, Ohira M . The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer. Springerplus. 2016; 5(1):1798. PMC: 5069226. DOI: 10.1186/s40064-016-3529-y. View